

Présentation de «E-ADV Application»

Bienvenue



2

SOMMAIRE

Objectif du projet

Scénario d'utilisation



Objectif du projet



Le laboratoire «Merck Serono » a comme objectif de mettre à la disposition de ses délégués médicaux une application qui fonctionne sur iPad leur permettant de présenter leurs produits aux clients qui sont répertoriés selon des catégories. Chaque produit comprend une liste de présentations et d'articles qui doivent être consultables d'une manière simple et conviviale.









Scénario de l'application

























 \mathbf{m}

is normally dissolved in blood, into long strands of fibrin that radiate from the clumped platelets and form a net that entraps more platelets and blood cells. The fibrin strands add bulk to the developing clot and help hold it in place to keep the vessel wall plugged.

The reactions that result in the formation of a blood clot are balanced by other reactions that stop the clotting process and dissolve clots after the blood vessel has healed. Without this control system, minor blood vessel injuries could trigger widespread clotting throughout the body—which actually happens in some diseases.



When an injury causes a blood vessel wall to break, platelets are activated. They change shape from round to spiny, stick to the broken vessel wall and each other, and begin to plug the break. They also interact with other blood proteins to form fibrin. Fibrin strands form a net that entraps more platelets and blood cells, producing a clot







HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use AFLURIA safely and effectively. See full prescribing information for AFLURIA.

AFLURIA, Influenza Vaccine Suspension for Intramuscular Injection 2013-2014 Formula Initial U.S. Approval: 2007

- INDICATIONS AND USAGE -

- AFLURIA is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B present in the vaccine. (1)
- AFLURIA is approved for use in persons 5 years of age and older. (1)

DOSAGE AND ADMINISTRATION

For intramuscular (IM) injection only (0.5 mL). (2.2)

Age	Dose/Route	Schedule	
5 years through 8 years	0.5 mL IM	One dose or two doses at least 1 month apart	
9 years and older	0.5 mL IM	One dose	

*1 or 2 doses depends on vaccination history as per Advisory Committee on Immunization Practices annual recommendations on prevention and control of influenza with vaccines. (2.1)

DOSAGE FORMS AND STRENGTHS

AFLURIA is a suspension for injection supplied in two presentations:

- 0.5 mL pre-filled syringe (single dose) (3, 11)
- . 5 ml. multi-dose vial (ten 0.5 ml. doses) (3, 11)

— CONTRAINDICATIONS —

 Severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine including egg protein, or to a previous dose of any influenza vaccine. (4, 11).

- WARNINGS AND PRECAUTIONS -

 Administration of CSL's 2010 Southern Hemisphere influenza vaccine was associated with increased rates of fever and febrile seizures in children predominantly below the age of 5 years as compared to previous years.
 Febrile events were also observed in children 5 to less than 9 years of age.
 (5.1)

- If Guillain-Barré Syndrome (GBS) has occurred within 6 weeks of previous influenza vaccination, the decision to give AFLURIA should be based on careful consideration of the potential benefits and risks. (5.2)
- Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.
 (5.3)
- Immunocompromised persons may have a diminished immune response to AFLURIA. (5.4)

- ADVERSE REACTIONS -

- In children 5 through 17 years of age, the most common injection-site adverse reactions were pain (≥60%), redness (≥20%) and swelling (≥10%).
 The most common systemic adverse reactions were headache, myalgia (≥20%), malaise and fever (≥10%), (6.1)
- In adults 18 through 64 years of age, the most common injection-site adverse reactions were tenderness (≥60%) and pain (≥40%). The most common systemic adverse reactions were headache, malaise, and muscle aches (≥20%). (6.1)
- In adults 65 years of age and older, the most common injection-site adverse reactions were tenderness (≥30%) and pain (≥10%). (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. at 1-877-888-4231 or VAERS at 1-800-822-7967 or www.vaers.bhs.gov.

To report SUSPECTED ADVERSE REACTIONS, contact at or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch


USE IN SPECIFIC POPULATIONS -

- Safety and effectiveness of AFLURIA have not been established in pregnant women or nursing mothers. (8.1, 8.3)
- Antibody responses were lower in geriatric subjects than in younger subjects. (8.5)
- AFLURIA is not approved for use in children less than 5 years of age because of increased rates of fever and febrile seizures. One comparatorcontrolled trial demonstrated higher rates of fever in recipients of AFLURIA as compared to a trivalent inactivated influenza vaccine control. (8.4)


See 17 for PATIENT COUNSELING INFORMATION

Revised: 07/2013










E-ADV BackOffice











Contenu

Commentaires

Rapports






Contenu


Commentaires

Rapports




Nom du fichier	Туре	Date	Commentaire	Lire	Supprimer
Fichier 1	Présentation	02-05-2014	Detail commentaire	/	
Fichier 2	Présentation	02-05-2014	Detail commentaire		
Fichier 3	Article	02-05-2014	Detail commentaire		
Fichier 4	Article	02-05-2014	Detail commentaire		
Fichier 5	Article	02-05-2014	Detail commentaire	1	
			< 1	2 3	4 5 >










Contenu

Commentaires

Rapports




Rapport numérique				▼ Filtre	
Présentation	Nbr de visite	Date de visite	Temps passer(par Prez)	Satisfaction	
Présenation produit 1	5	01-06-2014	00:15:32	Like	60%
Présenation produit 2	2	01-06-2014	00:15:32	Like	100%
Présenation produit 3	10	01-06-2014	00:15:32	Like	20%
Présenation produit 4	2	01-06-2014	00:15:32	Like	40%
Présenation produit 5	10	01-06-2014	00:15:32	Like	30%

Contenu

Commentaires

Rapports





				₹ Filtre
Nor de visite	Date de visite	Temps passer(par Pre	Satisfactio	n
5	01-06-2014	00:15:32	Like	60%
2	01-06-2014	00:15:32	Like	100%
10	01-06-2014	00:15:32	Like	20%
2	01-06-2014	00:15:32	Like	40%
10	01-06-2014	00:15:32	Like	30%
	5 2 10 2	5 01-06-2014 2 01-06-2014 10 01-06-2014 2 01-06-2014	5 01-06-2014 00:15:32 2 01-06-2014 00:15:32 10 01-06-2014 00:15:32 2 01-06-2014 00:15:32	5 01-06-2014 00:15:32 Like 2 01-06-2014 00:15:32 Like 10 01-06-2014 00:15:32 Like 2 01-06-2014 00:15:32 Like



